Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CFI-400945 is an orally active, potent, and selective inhibitor of polo-like kinase 4.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 1,520.00 |
Description | CFI-400945 is an orally active, potent, and selective inhibitor of polo-like kinase 4. |
In vitro | In an assay using recombinant human PLK4, CFI-400945 inhibited PLK4 (IC50: 2.8 ± 1.4 nM and Ki: 0.26 ± 0.1 nM in an ATP competitive manner). CFI-400945 inhibited autophosphorylation of PLK4 at serine 305 (EC50: 12.3 nM in cells overexpressing PLK4). CFI-400945 showed no significant inhibitory activity against other PLK family members (PLK1, PLK2, and PLK3 with the IC50s of > 50 μM). In transfected HCT116 cells with TRKA, TRKB, and Tie2/TEK, the EC50 values were 84 nM, 88 nM, and 117 nM, respectively. CFI-400945 inhibited the activity of AURKA and AURKB with the EC50 value of 510 nM and 102 nM. CFI-400945 (≥ 200 nM) decreased the mean centriole number in asynchronous U2OS cells. CFI-400945 inhibited a panel of breast cancer cell growth with the GI50 of 14-165 nM [1]. |
In vivo | In mice, the maximum tolerated dose (MTD) of CFI-400945 for once-daily oral administration was estimated to be 7.5-9.5 mg/kg [1]. |
Molecular Weight | 650.72 |
Formula | C37H38N4O7 |
CAS No. | 1616420-30-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10mg/ml
Ethanol: ≤12mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CFI-400945 1616420-30-4 Others CFI400945 CFI 400945 inhibitor inhibit